Effect of Clinical Pharmacist Interventions on Prevention of Adverse Drug Events in Surgical Intensive Care Unit
暂无分享,去创建一个
Hee-Pyoung Park | Y. Cho | H. Kim | A. Kim | Kyunghee Park | Hannah Lee | Yong Yu | Minkyong Kang | Hyeyoung Lee
[1] M. Hiesmayr. Nutrition risk assessment in the ICU , 2012, Current opinion in clinical nutrition and metabolic care.
[2] J. Rothschild,et al. Analysis of risk factors for adverse drug events in critically ill patients* , 2012, Critical care medicine.
[3] M. Boermeester,et al. Cost-effectiveness of ward-based pharmacy care in surgical patients: protocol of the SUREPILL (Surgery & Pharmacy In Liaison) study , 2011, BMC health services research.
[4] Susanne M. Smorenburg,et al. On-ward participation of a hospital pharmacist in a Dutch intensive care unit reduces prescribing errors and related patient harm: an intervention study , 2010, Critical care.
[5] L. Køber,et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. , 2010, Archives of internal medicine.
[6] G. Drusano,et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] R. Henkin,et al. An Open-Label Controlled Trial of Theophylline for Treatment of Patients With Hyposmia , 2009, The American journal of the medical sciences.
[8] Michael D Howell,et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. , 2009, JAMA.
[9] C. A. Bond,et al. Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections* , 2008, Critical care medicine.
[10] B. Erstad,et al. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[11] Joan Costa,et al. Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom , 2007, Therapeutics and clinical risk management.
[12] S. Kane-Gill,et al. Adverse-drug-event rates for high-cost and high-use drugs in the intensive care unit. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[13] Imad F. Btaiche,et al. Metabolic complications of parenteral nutrition in adults, Part 2. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[14] Michael J Dooley,et al. A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals. , 2004, British journal of clinical pharmacology.
[15] M. Postma,et al. Impact of pharmacist recommendations on the cost of drug therapy in icu patients at a Malaysian hospital , 2003, Pharmacy World and Science.
[16] G. V. Berghe,et al. Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.
[17] D. A. White,et al. Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model. , 2001, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[18] D. Bates,et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. , 1999, JAMA.
[19] A. Levin,et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] M. Boeckh,et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. , 1997, Blood.
[21] D. Bates,et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. , 1997, Critical care medicine.
[22] A. Mutnick,et al. Cost savings and avoidance from clinical interventions. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[23] E. Goldstein,et al. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] R. Dagan,et al. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group , 1995, Antimicrobial agents and chemotherapy.
[25] A. Keren,et al. Suppression of ventricular arrhythmias by magnesium. , 1990, The American journal of cardiology.
[26] C. Neumann,et al. Safety of intravenous ciprofloxacin. A review. , 1989, The American journal of medicine.
[27] B. Katona,et al. Effect of a pharmacist's and a nurse's interventions on cost of drug therapy in a medical intensive-care unit. , 1989, American journal of hospital pharmacy.
[28] A. Shields,et al. THE USE OF RANITIDINE IN BONE MARROW TRANSPLANTATION: A Review Of 223 Cases , 1988, Transplantation.
[29] G. Calandra,et al. The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients. , 1986, The Journal of antimicrobial chemotherapy.
[30] S. Lerner,et al. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. , 1986, The American journal of medicine.
[31] J. Tredger,et al. Hepatotoxicity to sodium valproate: a review. , 1984, Gut.
[32] J. Gatell,et al. Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin , 1983, Antimicrobial Agents and Chemotherapy.
[33] C. R. Smith. Cefotaxime and cephalosporins: adverse reactions in perspective. , 1982, Reviews of infectious diseases.
[34] E. Antman,et al. Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. , 1980, The New England journal of medicine.
[35] H. Ikeuchi,et al. Evaluation of teicoplanin dosing designs to achieve a new target trough concentration , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[36] D. Richards,et al. Cefotetan , 2012, Drugs.
[37] G. Eliopoulos,et al. The Sanford guide to antimicrobial therapy , 2010 .
[38] B. Bistrian,et al. Intensive insulin therapy in critically ill patients. , 2002, The New England journal of medicine.
[39] D. Kelly. Liver complications of pediatric parenteral nutrition--epidemiology. , 1998, Nutrition.
[40] Mchardy Gg. A multicenter, double-blind trial of sucralfate and placebo in duodenal ulcer. , 1981 .
[41] G. McHardy. A multicenter, double-blind trial of sucralfate and placebo in duodenal ulcer. , 1981, Journal of clinical gastroenterology.